WASHINGTON, D.C. — January 13, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Kenneth Kelley, M.B.A., and Jordan Orange, M.D., Ph.D., to its Board of Trustees. Mr. Kelley is a Harvard Senior Advanced Leadership Fellow, focusing on global health, biosecurity and the market inefficiency leading to a lack of vaccines against neglected tropical diseases (NTDs) and emerging pandemic threats. Dr. Orange is chief of Immunology, Allergy and Rheumatology, and professor and section head for Immunology, Allergy and Rheumatology in the pediatrics department at Baylor College of Medicine.

“We are very pleased to welcome Ken and Jordan to our board and look forward to the invaluable guidance they will provide as we advance Sabin’s mission to address some of the most pressing global health challenges,” said Dr. Axel Hoos, chairman of the Sabin Board of Trustees. “Both bring extensive and varied expertise in the field of global health. We hope to draw from their experience to help the world’s poorest people by delivering advances in vaccine development and increased access to safe and effective health interventions.”

In addition to his work at Harvard, Mr. Kelley most recently served on the board of PaxVax, a specialty travel vaccine company, which he co-founded in 2007 and where he served as chief executive officer from 2008 to May 2015. He has more than 30 years of entrepreneurial, venture capital, operational and technical biotechnology experience. Mr. Kelley serves on the boards of public and private biotech companies where he has emphasized strategy, leadership development, and change management.

“I am excited to join Sabin at a time when new drugs, vaccines and diagnostic technologies are being developed that hold the potential to significantly improve health outcomes for vulnerable communities,” said Mr. Kelley. “Having worked in the field of vaccine research and development for many years, I understand the enormous need to make health care solutions for vaccine-preventable and infectious diseases more accessible and affordable for low-income populations.”

The addition of Dr. Orange to the Board of Trustees comes at a time when the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) is deepening its efforts to accelerate the development of a number of vaccine candidates. In addition to his work at Baylor, Dr. Orange is director of the Center for Human Immunobiology at Texas Children’s Hospital. He is a board-certified pediatrician with a clinical specialty in primary immunodeficiency disease. Dr. Orange has focused his research efforts on primary immunodeficiency diseases and human natural killer cell deficiencies.

“Few organizations have done more than Sabin to advocate for the elimination of NTDs and other preventable diseases,” said Dr. Orange. “I hope to build on its already strong partnership with Baylor College of Medicine and Texas Children’s Hospital, and Iook forward to working with other members of the board to explore new opportunities to advance Sabin’s mission.”


About the Sabin Vaccine Institute

The Sabin Vaccine Institute (Sabin) is a non-profit, 501(c)(3) organization of scientists, researchers and advocates dedicated to reducing needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs). Since its founding in 1993 in honor of Dr. Albert B. Sabin, the developer of the oral polio vaccine, Sabin has been at the forefront of global efforts to eliminate, prevent, and cure infectious and neglected tropical diseases.

Sabin develops new vaccines, advocates for increased use of existing vaccines and promotes expanded access to affordable medical treatments in collaboration with governments, academic institutions, scientists, medical professionals and other non-profit organizations. For more information, please visit www.sabin.org.

Media Contact
Kelly Toves
+1 (202) 621-1691